Phase II Study of Bevacizumab and Vorinostat for Recurrent WHO Grade IV Malignant Glioma Patients

Trial Profile

Phase II Study of Bevacizumab and Vorinostat for Recurrent WHO Grade IV Malignant Glioma Patients

Completed
Phase of Trial: Phase II

Latest Information Update: 10 Mar 2017

At a glance

  • Drugs Bevacizumab (Primary) ; Vorinostat (Primary)
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 16 Feb 2016 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov record.
    • 29 May 2015 Primary endpoint has not been met (6-month progression-free survival) according to results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 29 May 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top